<DOC>
	<DOC>NCT01721772</DOC>
	<brief_summary>The purpose of this study is to compare the clinical benefit, as measured by overall survival, of nivolumab with that of. dacarbazine in patients with previously untreated, unresectable, or metastatic melanoma</brief_summary>
	<brief_title>Study of Nivolumab (BMS-936558) Compared With Dacarbazine in Untreated, Unresectable, or Metastatic Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Men and women â‰¥18 years of age Eastern Cooperative Oncology Group Performance Status of 0 or 1 Untreated and histologically confirmed unresectable Stage III or Stage IV melanoma, as per the staging system of the American Joint Committee on Cancer Measurable disease as per Response Evaluation Criteria in Solid Tumors 1.1 Tumor tissue from an unresectable or metastatic site of disease must be provided for biomarker analyses Known BRAF wildtype, as per regionally acceptable V600 mutational status testing. BRAF mutant patients and those with indeterminate or unknown BRAF status are not permitted to randomize Active brain metastases or leptomeningeal metastases Ocular melanoma Any active, known, or suspected autoimmune disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>